Q-omics provides the consensus-scored MRI1 profile across patient tissues and cancer cell-line models. MRI1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MRI1 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, MRI1 RNA expression shows 19,537 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and COAD as cancer lineages where MRI1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MRI1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MRI1 survival associations across molecular data types. MRI1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MRI1 RNA expression–survival associations across cancer types. High MRI1 expression shows unfavorable associations in ACC, LGG, UVM and KIRP, but favorable associations in BRCA and SCLC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MRI1 RNA expression.
This table summarizes MRI1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for MRI1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MRI1 shows lower tumor expression in KICH and THCA and higher tumor expression in COAD, KIRC, HNSC and BLCA. The COAD box plot shows higher MRI1 RNA expression in tumor versus normal tissue (log2 FC = +1.086, t-test p < 0.001).
This table shows molecular features associated with MRI1 in patient tissues and cancer cell lines. In patient samples, MRI1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, MRI1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in LIVER and UPPER_AERODIGESTIVE_TRACT.
